Truvestments Capital LLC Neurocrine Biosciences Inc Transaction History

Truvestments Capital LLC

  • $363 Million
  • Q3 2024

A detailed history of Truvestments Capital LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Truvestments Capital LLC holds 544 shares of NBIX stock, worth $68,277. This represents 0.02% of its overall portfolio holdings.

Number of Shares
544
Holding current value
$68,277
% of portfolio
0.02%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$114.58 - $153.15 $62,331 - $83,313
544 New
544 $62,000
Q1 2024

May 14, 2024
BUY
$130.4 - $143.74 $38,859 - $42,834
298 Added 111.19%
566 $78,000
Q4 2022

Feb 13, 2023
SELL
$106.72 - $127.06 $90,178 - $107,365
-845 Reduced 75.92%
268 $32,000
Q2 2022

Aug 09, 2022
BUY
$75.79 - $100.07 $84,354 - $111,377
1,113 New
1,113 $108,000
Q1 2022

May 02, 2022
SELL
$72.45 - $94.81 $88,823 - $116,237
-1,226 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$79.65 - $106.22 $15,531 - $20,712
195 Added 18.91%
1,226 $104,000
Q3 2021

Oct 29, 2021
BUY
$86.18 - $99.03 $2,930 - $3,367
34 Added 3.41%
1,031 $99,000
Q2 2021

Aug 12, 2021
BUY
$89.43 - $102.27 $20,032 - $22,908
224 Added 28.98%
997 $97,000
Q1 2021

May 18, 2021
BUY
$87.57 - $119.4 $43,347 - $59,103
495 Added 178.06%
773 $75,000
Q4 2020

Feb 17, 2021
BUY
$86.91 - $108.33 $24,160 - $30,115
278 New
278 $26,000
Q3 2020

Nov 13, 2020
SELL
$96.16 - $135.15 $7,692 - $10,812
-80 Closed
0 $0
Q2 2020

Aug 06, 2020
BUY
$85.09 - $130.36 $935 - $1,433
11 Added 15.94%
80 $9,000
Q1 2020

May 07, 2020
BUY
$75.11 - $113.76 $5,182 - $7,849
69 New
69 $5,000
Q4 2019

Jan 29, 2020
SELL
$86.8 - $118.57 $3,298 - $4,505
-38 Closed
0 $0
Q3 2019

Oct 10, 2019
BUY
$83.82 - $101.5 $3,185 - $3,857
38 New
38 $3,000

Others Institutions Holding NBIX

# of Institutions
629
Shares Held
94.2M
Call Options Held
692K
Put Options Held
406K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Truvestments Capital LLC Portfolio

Follow Truvestments Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Truvestments Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Truvestments Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email